Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.

Company:

Axcella Health Inc.

 

 

Headquarters Address:

840 Memorial Dr., Third Floor

 

CAMBRIDGE, MA 02139

 

 

Main Telephone:

857-320-2200

 

 

Website:

www.axcellahealth.com

 

 

Ticker:

AXLA(NASDAQ)

 

 

Type of Organization:

Public

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Bill Hinshaw

 

 

Investor Relations

 

Contact:

Jason Fredette

Phone:

7814240946

Email:

jfredette@axcellahealth.com

 

Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Axcella Health Charts.
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Axcella Health Charts.